Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Major study aims to unlock mysteries of Early-Onset Alzheimer's

NCT ID NCT03507257

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study follows 850 people aged 40-64 with early-onset cognitive impairment to understand how Alzheimer's disease progresses. Participants undergo cognitive tests, brain scans, and genetic analysis, but no experimental treatment is given. The goal is to gather data that could improve future diagnosis and care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 850 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2018

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cognitively Impaired Participants (ie: Early Onset Alzheimer's Disease (EOAD) and Early Onset non-Alzheimer's Disease (EOnonAD)) and Cognitively Normal (CN) Control Participants

Ages

40 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Cognitively Impaired (EOAD and EOnonAD) Cohorts Only: 1. Meets NIA-AA criteria for MCI due to AD or probable AD dementia 2. Have a global CDR score ≤ 1.0 3. Have capacity to provide informed consent (IC) or has a legal authorized representative or guardian who provides IC 4. Age between 40-64 years (inclusive) at the time of consent 5. Must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, caregiver) who is generally aware of the participants' daily activities and can provide information about the participant's cognitive and functional performance. If the participant does not have a study partner who spends at least 10 face-to-face hours per week, other arrangements for identifying a viable study partner will be granted on a case-by-case basis by the Site PI 6. Willing and able to complete longitudinal study procedures aside from LP which is an optional procedure 7. Not pregnant or lactating. Women must be two years post-menopausal, be surgically sterile, or have a negative pregnancy test prior to each PET scan 8. Fluent in English or Spanish if enrolled in the U.S. 9. Fluent in English, Spanish, Dutch or Swedish for sites outside the U.S., according to site's spoken language(s). Inclusion Criteria for Cognitively Normal (CN) Cohort Only: 1. Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living 2. Have a global CDR score = 0 3. Have capacity to provide informed consent 4. Have a Mini-Mental State Exam score between 26-30 (inclusive). Exceptions may be made for participant with less than 8 years of education at the discretion of the Site PI 5. Age between 40-64 years (inclusive) at the time of consent 6. Must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, caregiver) who is generally aware of the participants' daily activities and can provide information about the participant's cognitive and functional performance. If the participant does not have a study partner who spends 10 face-to-face hours per week, other arrangements for identifying a viable study partner will be granted on a case-by-case basis by the Site PI 7. Willing and able to complete longitudinal study procedures aside from LP which is an optional procedure 8. Not pregnant or lactating. Women must be two years post-menopausal, be surgically sterile, or have a negative pregnancy test prior to each PET scan 9. Fluent in English or Spanish if enrolled in the U.S. 10. Fluent in English, Spanish, Dutch or Swedish for sites outside the U.S., according to site's spoken language(s). Exclusion Criteria for all (EOAD, EOnonAD and CN) cohorts: 1. Meets core clinical criteria for non-AD dementia 2. Two or more first degree relatives with a history of early-onset dementia suggestive of autosomal dominant transmission, unless known pathogenic mutations in APP, PSEN1, PSEN2, MAPT, GRN and C9ORF72 have been excluded 3. Known CLIA certified mutation in an ADAD gene (APP, PSEN1, PSEN2), or other autosomal dominant genes associated with other neurodegenerative disorders (MAPT, GRN, C9ORF72) 4. Contraindications to 3T MRI (e.g., claustrophobia, pacemaker, select aneurismal clip, artificial heart valve, select ear implants, select stents incompatible with 3T MRI, metal fragments or foreign objects in the eyes, skin or body, etc.) 5. Lifetime medical history of a brain disorder other than the disorder causing dementia except for headache (exceptions are allowed at the discretion of the Site PI - e.g., seizure disorder thought to be due to EOAD). 6. MRI scan with evidence of infection or focal lesions, cortical strokes, multiple lacunes (single lacune is allowable unless it meets criteria for strategic lacune affecting cognition) 7. Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol (at the discretion of the Site PI) 8. Research radiation exposure will be assessed by the study physician. If the candidate participant has had more than one nuclear medicine study in the prior 12 months for research-related purposes, study inclusion will require approval from the PET Core 9. Investigational agents are prohibited 30 days prior to entry 10. Previous enrollment in a therapeutic trial targeting amyloid or tau. 11. Participation in other clinical studies with neuropsychological measures, with the exception of participants who are co-enrolled in the NACC Uniform Data Set (UDS) protocol (Note: This criterion is intended to reduce repeat measures effects during neuropsychological testing. Exceptions are allowed at the discretion of the Site PI) 12. Lifetime history of schizophrenia spectrum disorders (DSM-5 criteria) 13. Current history (in previous 12 months) of DSM-5 diagnosis of mania, bipolar disorder with or without psychotic features 14. Current history (in previous 6 months) of moderate or severe substance abuse (nicotine or caffeine is allowed) 15. Suicidal behaviors in the past 12 months or active suicidal ideations 16. Residing in a 24-hour care skilled nursing facility (at the time of screening) 17. (For optional lumbar puncture procedure only): a. Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be not clinically significant by the Site PI i. Platelet count \<100,000/ml ii. INR\>1.2 iii. Abnormal PT or PTT at screening b. Contraindications to the procedure, including but not limited to severe degenerative joint disease, deformity of the spine, history of a bleeding disorder c. Suspected elevated intracranial pressure, Arnold Chiari malformation or mass lesion d. Use of the anticoagulant medications such as but not limited to warfarin, rivaroxaban, dabigatran 18. Deemed ineligible by the Site PI for any other reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam UMC

    Amsterdam, 1081 HZ, Netherlands

  • Banner Sun Health Research Institute

    Sun City, Arizona, 85351, United States

  • Butler Hospital

    Providence, Rhode Island, 02906, United States

  • Columbia University

    New York, New York, 10032, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Fleni

    Buenos Aires, C1428 CABA, Argentina

  • Georgetown University

    Washington D.C., District of Columbia, 20057, United States

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 8041, Spain

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

  • Indiana University

    Indianapolis, Indiana, 47405, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21218, United States

  • Lund University

    Malmö, 214 28, Sweden

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic, Jacksonville

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic, Rochester

    Rochester, Minnesota, 55905, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Stanford University

    Palo Alto, California, 94304, United States

  • University College London

    London, WC1N 3BG, United Kingdom

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, San Francisco

    San Francisco, California, 94121, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Washington University, St. Louis

    St Louis, Missouri, 63130, United States

  • Wien Center

    Miami Beach, Florida, 33140, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.